Innovative Drug Delivery Solution: The Integration of Microorganism Micro-Engine and Microneedle Technology

1. Overview of Microneedle Technology and Its Limitations

1.1 Overview of Microneedles

Microneedles are a minimally invasive transdermal drug delivery technology designed to penetrate the stratum corneum, enabling effective drug administration. Unlike traditional hypodermic needles, microneedles are short and fine, causing minimal pain and reducing the risk of infection by avoiding direct contact with nerves and blood vessels.
This technology is widely applied in drug delivery, vaccine administration, gene therapy, and cosmetic dermatology.

 

1.2 Mechanism of Microneedles

Microneedles penetrate the outermost layer of the skin, the stratum corneum, and deliver drugs into the epidermis or dermis. Compared to conventional transdermal patches, microneedles enable deeper and more effective drug penetration.
Microneedles can be classified into the following types:

1. Solid Microneedles
• Create micro-channels in the skin for subsequent drug absorption.
• Improve skin permeability but have a slow drug delivery rate.
2. Dissolvable Microneedles
• Made from biodegradable polymers containing drugs.
• Dissolve upon insertion, gradually releasing the drug.
3. Coated Microneedles
• Drugs are coated onto the needle’s surface, which dissolves upon skin insertion.
• Provide rapid drug release but have limited drug capacity.
4. Polymeric Microneedles
• Constructed from biocompatible polymers, allowing versatile drug delivery.
• Extensively studied for transdermal vaccines and gene therapy.
5. Metal/Silicon Microneedles
• Offer high mechanical strength and precise control.
• Can be integrated with wearable medical devices for continuous drug delivery.

 

1.3 Limitations of Conventional Microneedle Technology

Despite their numerous advantages, conventional microneedles have several limitations:

1. Limited Passive Drug Diffusion
• Drug penetration relies on passive diffusion, making precise control over depth and rate difficult.
• Limited effectiveness for thick skin areas (e.g., soles and palms) or deep tissue drug delivery.
2. Restricted Drug Capacity
• Microneedles have limited volume, making it challenging to deliver large doses.
• Compared to injections, large-scale or sustained drug release is difficult.
3. Compatibility Issues with Specific Drugs
• Large-molecule drugs, including proteins, vaccines, and gene therapies, may suffer from stability issues.
• Poor skin penetration necessitates additional technological enhancements.
4. Challenges in Precise Drug Control
• Conventional microneedles lack active control over drug diffusion.
• Targeting specific tissues or personalized medicine is difficult.
5. Mechanical Strength and Breakage Risks
• Some polymeric and dissolvable microneedles may break upon insertion.
• Broken microneedles may cause tissue damage or inflammation.

 

1.4 Innovative Approaches to Overcome Limitations

To address these challenges, researchers have proposed several cutting-edge solutions:

✅ Active Drug Delivery Microneedles

• Transitioning from passive diffusion to active delivery using electric fields, ultrasound, magnetic fields, or gas pressure.

✅ Bioresponsive Microneedles

• Insulin microneedles responsive to blood glucose levels for diabetes treatment.
• Temperature-sensitive microneedles for controlled drug release based on body heat.

✅ Nanoparticle and Gene Therapy Applications

• Embedding nanoparticles in microneedles for targeted drug delivery.
• CRISPR-based gene therapy microneedles for genetic disease treatment.

✅ Microorganism Micro-Engine-Based Microneedles

• Utilizing gas-producing microorganisms (e.g., Enterobacter aerogenes) to actively propel drugs into deeper tissues.
• 200% increase in drug penetration depth, offering precise control.

 

Microneedles represent an innovative, non-invasive drug delivery system; however, conventional approaches still struggle with passive control, limited drug capacity, and compatibility with large-molecule drugs.
To overcome these limitations, advancements in electromagnetic control, nanotechnology, bioresponsive materials, and microorganism-powered drug delivery are actively being explored, ensuring continuous evolution in microneedle technology.

 

2. Overview of Microorganism-Based Microneedle Micro-Engine Technology

2.1 What is a Microorganism-Based Micro-Engine?

A microorganism-based micro-engine is a technology that enhances drug delivery by utilizing the active biological properties of microorganisms within the body. Traditional microneedles rely on passive diffusion, which makes it difficult to control drug penetration depth and release speed. To overcome this limitation, researchers have developed a new approach using gas propulsion generated by microorganisms to actively deliver drugs.

This technology involves encapsulating specific microorganisms, such as Enterobacter aerogenes, within microneedles. These microorganisms ferment glucose or other substrates, producing gas that propels the drug deeper into tissues.

 

2.2 Differences from Conventional Microneedles

Conventional microneedles release drugs into the skin through natural diffusion, which lacks precise control over drug penetration depth. However, microorganism-based micro-engine microneedles offer several key advantages:

✅ Active Drug Delivery:

• Utilizes microorganism-generated gas to actively push drugs to the desired depth
• 200% increase in penetration depth (up to 1,000 μm) compared to conventional microneedles

✅ Adjustable Drug Release Rate:

• The concentration of glucose can be adjusted to regulate gas production speed, thereby controlling drug release rates

✅ Targeted Drug Delivery:

• Uses gas pressure inside the skin to push drugs toward specific locations
• Enables greater precision compared to conventional microneedles

 

2.3 Mechanism of Microorganism-Based Micro-Engine

The core principle of a microorganism-based micro-engine is leveraging gas production from the metabolic activity of Enterobacter aerogenes. This microorganism can ferment glucose, generating hydrogen (H₂) and other gases, which actively propel the drug.

🔹 Key Operating Steps:

1. Microneedle Insertion:
• Microorganism-encapsulated microneedles are inserted into the skin
2. Microbial Gas Production:
• Enterobacter aerogenes inside the microneedle ferments glucose, producing gas
• The increasing gas pressure propels the drug into deeper tissue layers
3. Drug Delivery and Diffusion:
• Generated gas actively pushes the drug beyond 1,000 μm into the skin
• Compared to conventional microneedles, this technology enhances drug diffusion speed and coverage

 

2.4 Key Advantages of Microorganism-Based Micro-Engine

✅ Overcomes the Limitations of Conventional Drug Delivery:

• Addresses drug capacity and penetration depth limitations of dissolvable microneedles
• Ensures effective drug delivery even in thick-skinned areas

✅ Non-Invasive and Low Irritation:

• Minimizes pain and infection risks compared to traditional injections

✅ Compatible with Various Drugs:

• Can be applied to vaccines, gene therapies, anticancer drugs, and other pharmaceutical applications

✅ Personalized Treatment Possibilities:

• The rate of gas production can be controlled, enabling customized drug release for patients

 

2.5 Current Research Progress and Future Outlook

The microorganism-based micro-engine microneedle technology has shown promising results in laboratory and animal studies, demonstrating potential for various applications.

💡 Future Research Directions:

• Expanding Microbial Utilization:

• Exploring oxygen (O₂) and carbon dioxide (CO₂)-producing microbes to diversify drug delivery mechanisms

• Developing Smart Microneedles:

• Researching sensor-based microneedles that respond to skin conditions (temperature, pH changes, etc.)

• Clinical Trials and Commercialization Prospects:

• Expected clinical trials and potential FDA approval within five years
• Potential integration with wearable medical devices for remote drug administration

 

Microorganism-based micro-engine microneedles overcome the limitations of conventional microneedles, providing deeper and more precise drug delivery. This technology holds great potential for vaccines, cancer treatment, and chronic disease management, and is expected to advance toward clinical trials and commercialization in the near future.

 

3. Mechanism of Microorganism-Based Micro-Engine

3.1 Overview of Microorganism-Based Micro-Engine

A microorganism-based micro-engine is an innovative technology that utilizes gas propulsion generated by microorganisms to actively deliver drugs. Traditional microneedles rely on passive drug diffusion, which makes it difficult to control the penetration depth and drug release rate.

To address this limitation, researchers have developed a method using gas-producing microorganisms such as Enterobacter aerogenes to propel drugs into deeper tissues. This technology allows precise control over drug delivery depth and speed, achieving a 200% increase in penetration depth compared to conventional microneedles.

 

3.2 Operating Mechanism of Microorganism-Based Micro-Engine

The working process of the microorganism-based micro-engine consists of the following steps:

1. Microneedle Insertion:
• Microorganism-encapsulated microneedles are applied to the skin.
2. Microbial Activation and Gas Generation:
• Enterobacter aerogenes inside the microneedles ferments glucose, producing hydrogen (H₂) and carbon dioxide (CO₂).
• The amount of gas generated can be controlled by adjusting glucose concentration.
3. Increase in Gas Pressure and Drug Propulsion:
• Gas production increases internal pressure, actively pushing the drug deeper into the skin.
• Compared to conventional microneedles, drugs can penetrate up to 1,000 μm into the skin.
4. Drug Release and Diffusion:
• The generated gas propels the drug into the target site, ensuring precise delivery to the required depth.

 

3.3 Optimizing Drug Delivery Through Gas Generation Control

One of the key advantages of microorganism-based micro-engines is the ability to control gas generation to optimize drug delivery:

• Glucose Concentration Regulation:

• Increasing glucose concentration enhances gas generation, allowing deeper drug penetration.
• Lower glucose concentration reduces gas generation, leading to slower drug release.

• Customized Drug Release:

• The gas production rate can be adjusted based on the patient's condition, enabling personalized drug delivery.

 

3.4 Advantages of Microorganism-Based Micro-Engine

✅ Overcoming Limitations of Conventional Microneedles

• Shifts from passive diffusion to actively driven drug delivery.
• Ensures drug penetration into deeper tissues, regardless of skin thickness.

✅ Non-Invasive and Highly Efficient

• Less painful and lower risk of infection compared to traditional injections.
• Gas-powered active delivery enables rapid and precise drug release.

✅ Applicable to Various Disease Treatments

• Potential applications in vaccines, gene therapy, cancer treatment, and inflammatory diseases.
• Enables targeted therapy, enhancing drug efficacy while minimizing systemic exposure.

 

3.5 Research Progress and Future Prospects

Currently, microorganism-based micro-engine microneedles have shown promising results in laboratory and animal models, with a high potential for clinical applications.

💡 Future Research Directions:

• Expanding the Use of Different Microorganisms:

• Research is underway to utilize therapeutic gas-producing microorganisms that generate oxygen (O₂), nitric oxide (NO), and other bioactive gases.

• Development of Smart Microneedles:

• Sensor-based microneedles that respond to physiological conditions (temperature, pH levels, etc.) are under development.

• Integration with Wearable Medical Devices:

• Possibility of remote drug administration systems.
• Potential for integration with smart healthcare devices for real-time drug release control.

 

Microorganism-based micro-engine microneedles overcome the limitations of conventional microneedles, providing deeper and more precise drug delivery. This technology is expected to play a crucial role in vaccine delivery, chronic disease treatment, cancer therapy, and gene therapy. With continued clinical trials and technological advancements, the likelihood of commercialization in the near future is high.

 

4. Analysis of Drug Delivery Performance of Microorganism Micro-Engine Microneedles

4.1 Drug Delivery Efficiency of Microorganism Micro-Engine Microneedles

Microorganism-based micro-engine microneedles enable active drug delivery, significantly improving drug penetration depth and precision compared to conventional microneedles. Unlike conventional microneedles, which rely solely on passive diffusion, the gas propulsion mechanism in microorganism-based micro-engines allows drugs to be delivered over 1,000 μm into the skin, resulting in a 200% increase in penetration depth.

 

4.2 Experimental Performance Validation

To verify the performance of microorganism micro-engine microneedles, researchers conducted various experiments:

1. Dye Diffusion Test
• Rhodamine dye was used to visually confirm the penetration depth of microneedles.
• Microorganism micro-engine microneedles showed over twice the penetration depth compared to conventional microneedles.
2. Drug Absorption Experiment in Animal Models
• BALB/c mice were used to measure drug concentration within the skin.
• Under high glucose concentration (30 mg/mL), drug penetration depth was three times greater than conventional microneedles.
• High-resolution microscopy confirmed that the drug reached deep blood vessels within the tissue.
3. Drug Delivery Rate Assessment
• Blood drug concentration was analyzed over time after microneedle application.
• Microorganism micro-engine microneedles enabled continuous drug release for 24 hours, prolonging drug retention compared to conventional microneedles.

 

4.3 Comparative Analysis of Skin Penetration Ability

Microneedle Type	Penetration Depth (μm)	Drug Diffusion Area (mm²)	Drug Release Duration (h)
Conventional Microneedles	400-500	3.2	6-12
Microorganism Micro-Engine Microneedles	900-1,200	7.8	24-48

 

4.4 Stability Evaluation of Microorganism-Based Microneedles

To ensure the long-term biocompatibility and safety of microorganism micro-engine microneedles in biological environments, researchers conducted the following stability tests:

• Microorganism Viability Assessment
• The survival rate of encapsulated microorganisms within microneedles was monitored for 48 hours.
• At 25°C, over 90% of microorganisms remained active after 24 hours.
• At 4°C storage, over 95% viability was maintained for 48 hours.
• Skin Tissue Response Experiment
• The impact of microorganism micro-engine microneedles on skin tissue was evaluated.
• Minimal skin inflammation was observed, and no significant cell damage was detected through histological analysis.

 

4.5 Summary and Conclusion of Experimental Results

• Microorganism micro-engine microneedles deliver drugs 2-3 times deeper than conventional microneedles.
• The duration of drug release extended from 6-12 hours to 24-48 hours.
• High biocompatibility was demonstrated, ensuring long-term safety for extended use.

These findings confirm that microorganism micro-engine microneedles provide precise and deeper drug delivery, making them highly effective for sustained drug release applications. This technology has significant potential for chronic disease treatment, vaccine delivery, and gene therapy, demonstrating broad applications in various medical fields.

 

5. Application of Microorganism Micro-Engine Microneedles in Psoriasis Treatment

5.1 Characteristics of Psoriasis and the Need for Treatment

Psoriasis is a chronic inflammatory skin disease characterized by an overactive immune response that causes skin cells to proliferate at an abnormally high rate. This leads to erythema, scaling (keratin buildup), and itching. Since psoriasis remains an incurable condition, long-term management is necessary.

Current treatments include topical steroids, phototherapy, and immunosuppressants, but they often come with significant side effects and limited skin penetration efficiency.

 

5.2 Application of Microorganism Micro-Engine Microneedles for Psoriasis Treatment

Microorganism micro-engine microneedles offer an innovative approach that overcomes the limitations of conventional treatments by delivering therapeutic agents more effectively.

By utilizing microorganism-based gas propulsion, these microneedles can transport anti-inflammatory agents and immunomodulators deep into psoriasis-affected skin, achieving higher biocompatibility and prolonged therapeutic effects compared to conventional treatments.

 

5.3 Experimental Studies and Findings

Researchers developed microorganism micro-engine microneedles containing Calcipotriol, a psoriasis treatment drug, and conducted animal model studies to evaluate their effectiveness.

1. Comparison of Drug Delivery in Psoriasis-Model Mice
• Control group: Traditional topical cream application
• Experimental group: Microorganism micro-engine microneedle-based drug delivery
• Results:
• The epidermal thickness reduction rate increased by 45% in the microneedle-treated group.
• The expression of inflammatory cytokines (IL-17A, IL-22, IL-23) significantly decreased in the microneedle-treated group.
2. Drug Penetration Depth and Sustained Release Effect
• Tissue staining and penetration analysis revealed that microorganism micro-engine microneedles delivered drugs three times deeper than conventional topical formulations.
• Even 24 hours post-application, drug concentration remained high, indicating a longer-lasting therapeutic effect compared to conventional treatments.

 

5.4 Advantages of Microorganism Micro-Engine Microneedles

✅ Maximized Drug Delivery Efficiency:

• Overcomes the limited penetration of conventional topical treatments.
• Enables direct treatment of inflamed deep tissues.

✅ Reduced Side Effects and Improved Patient Compliance:

• Minimizes systemic side effects (e.g., hepatotoxicity and immunosuppression) associated with traditional immunosuppressants.
• Less invasive and nearly painless compared to injection-based treatments.

✅ Potential for Long-Term Treatment:

• A single microneedle application provides prolonged drug release.
• Sustained drug release time increased threefold compared to conventional treatments.

 

5.5 Clinical Applications and Future Research Directions

Microorganism micro-engine microneedles are considered a promising technology for psoriasis treatment. Further clinical trials will be conducted to validate their efficacy and explore broader applications.

💡 Future Research Directions:

• Combination therapy testing with other psoriasis treatments (e.g., biologics, steroid-loaded microneedles).
• Development of personalized treatment models, where drug release is tailored based on an individual’s immune response and skin properties.
• Expansion to other inflammatory skin conditions such as atopic dermatitis and vitiligo.

 

Microorganism micro-engine microneedles overcome the limitations of conventional psoriasis treatments, offering a more precise and effective therapy. They also show potential for treating various other inflammatory skin diseases, making them a strong candidate for future clinical applications and commercialization.

 

6. Future Prospects: Expansion Potential of Microorganism Micro-Engine Technology

6.1 Current Status of Microorganism Micro-Engine Technology

Microorganism micro-engine technology is currently at the research stage, being tested in laboratories and animal models. With its ability to overcome the limitations of conventional microneedles by enabling more precise drug delivery, this technology is gaining significant attention in the medical and biotech industries.

 

6.2 Potential Applications in the Medical Field

Beyond psoriasis treatment, microorganism micro-engine technology has the potential to expand into various disease treatments and medical applications.

✅ Cancer Therapy

• Can be utilized to enhance targeted drug delivery for cancer treatments.
• Minimizes side effects of traditional chemotherapy while delivering drugs exclusively to tumor sites.

✅ Chronic Disease Treatment

• Potential development of sustained-release insulin microneedles for diabetes management.
• Research is ongoing to apply transdermal extended-release drugs for cardiovascular disease treatments.

✅ Gene Therapy & Vaccine Development

• Applicable for transdermal administration of DNA and RNA-based vaccines.
• Enhances cellular uptake of gene therapies, maximizing therapeutic efficiency.

 

6.3 Integration with Smart Healthcare

Microorganism micro-engine microneedles have a high potential to be integrated with wearable devices and smart healthcare systems.

• Real-time monitoring capabilities (e.g., blood glucose, inflammation levels).
• Personalized drug release control, adjustable via smartphone apps.
• IoT-based remote medical treatment, enabling telemedicine applications.

 

6.4 Industrial and Market Growth Potential

Microorganism micro-engine technology is expected to witness substantial growth in the pharmaceutical and biotech industries.

📈 Market Forecast:

• The microneedle drug delivery system market was valued at $3 billion in 2024 and is projected to grow to $4.18 billion by 2029.
• Market share of microorganism-based drug delivery technologies is expected to rise.

📌 Key Investment and Research Trends:

• Global pharmaceutical and biotech companies are increasing investments and patent filings related to microorganism micro-engine technology.
• Regulatory agencies such as the FDA and EMA are establishing guidelines for approval processes for next-generation drug delivery systems.

 

7. Research and Economic Challenges for the Commercialization of Microorganism Micro-Engine Technology

7.1 Technical Challenges and Solutions

While microorganism micro-engine-based microneedle technology represents an innovative drug delivery method, several technical hurdles must be addressed for successful commercialization.

✅ Ensuring Microbial Safety in the Body

• Microorganisms may trigger unpredictable immune responses when introduced into the body.
• Solution: Utilize non-pathogenic strains or genetically modify microorganisms to minimize immune response risks.

✅ Development of Gas Generation Control Technology

• Variability in microbial metabolic activity makes it challenging to precisely regulate drug delivery speed.
• Solution: Develop methods for substrate concentration adjustment and integrate external sensors to monitor gas production.

✅ Long-Term Storage and Distribution Issues

• Microorganisms within microneedles may lose viability over extended storage periods.
• Solution: Implement freeze-drying and nanoencapsulation technologies to improve microbial survival rates.

 

7.2 Economic and Industrial Barriers

The research and development (R&D) required to commercialize microorganism micro-engine technology demands significant investment, and various industrial challenges must be addressed.

✅ High Production Costs

• The use of biocompatible materials and microneedle manufacturing processes is more expensive than conventional drug delivery methods.
• Solution: Establish mass production techniques and adopt cost-reduction strategies.

✅ Regulatory Approval (R&D and Clinical Trials) Challenges

• Obtaining regulatory approval from global agencies such as the FDA and EMA requires lengthy clinical trials and safety evaluations.
• Solution: Incorporate regulatory requirements early in the research phase and collaborate with regulatory bodies to streamline approval processes.

✅ Market Entry Barriers and Competition with Existing Technologies

• Competing with established drug delivery methods such as oral medications and intravenous injections may make it difficult to secure market share.
• Solution: Demonstrate superior clinical efficacy compared to existing treatments and conduct studies on patient and physician acceptance.

 

7.3 Strategies for Commercializing Microorganism Micro-Engine Technology

📌 Enhancing Industry-Academia Collaboration

• Foster partnerships with universities and research institutions to accelerate technology development.
• Strengthen collaborations with global pharmaceutical and biotech companies.

📌 Targeting Initial Market Applications

• Early commercialization should focus on vaccine delivery, chronic disease treatment, and dermatological applications, where microneedle technology has already succeeded.
• Expansion into high-value markets such as cancer treatment and neurological disorders should follow.

📌 Regulatory Compliance and Clinical Research Enhancement

• Maintain continuous cooperation with regulatory bodies to ensure compliance with evolving standards.
• Conduct multinational clinical trials to generate reliable data supporting the technology’s effectiveness.

 

Microorganism micro-engine microneedles present a next-generation drug delivery system with tremendous potential, but technical, economic, and regulatory challenges must be overcome before commercialization.

To achieve widespread adoption, it is crucial to ensure safety, reduce mass production costs, and develop a strategic regulatory approval process. Ongoing R&D efforts and industrial collaboration will be essential in this process.

If these challenges are successfully addressed, microorganism micro-engine technology has the potential to revolutionize the global medical industry by providing innovative treatment solutions.

 

8. Final Summary and Conclusion

8.1 Summary of Key Findings

Microorganism micro-engine-based microneedle technology overcomes the limitations of conventional drug delivery methods and is regarded as an innovative solution for deeper and more precise drug administration.

🔹 Limitations of Conventional Microneedles

• Passive drug diffusion makes it difficult to control delivery depth and speed.
• Challenges in penetrating deep into the skin and effectively reaching target tissues.

🔹 Key Advantages of Microorganism Micro-Engine Microneedles

• Gas propulsion mechanism enables active drug delivery.
• Up to 200% increase in skin penetration depth compared to conventional microneedles.
• Extended drug release duration, making it suitable for chronic disease treatment.
• Applicable to various medical fields, including vaccination, cancer therapy, and neurological disorders.

 

8.2 Research and Technological Advancements

✅ Ensuring Biocompatibility and Safety of Microorganisms

• Research is required to ensure the long-term safety of microorganisms in the body.
• Development of genetically modified strains to minimize immune response.

✅ Development of Personalized Drug Delivery Systems

• Integration with smart healthcare for customized drug release control.
• Real-time monitoring using IoT and wearable devices.

✅ Regulatory Approval and Commercialization Strategies

• Collaboration with global regulatory agencies (FDA, EMA) is essential.
• Clinical trials are necessary to verify safety and efficacy.
• Mass production techniques must be developed to reduce costs.

 

8.3 Future Prospects of Microorganism Micro-Engine Technology

This technology has the potential to revolutionize drug delivery methods and establish a new paradigm in the medical field.

📌 Short-Term Outlook (Within 5 Years)

• High potential for commercialization in initial applications such as vaccines, dermatology, and chronic disease treatment.
• Expected to outperform conventional microneedles in drug delivery efficiency.

📌 Long-Term Outlook (Beyond 10 Years)

• Expansion into advanced personalized therapy fields, such as cancer treatment, neurological disorders, and gene therapy.
• Integration with smart healthcare and remote medical systems, evolving into digital therapeutics.

 

8.4 Final Conclusion

Microorganism micro-engine microneedles overcome the limitations of conventional drug delivery systems and offer a more effective and precise therapeutic approach. With continued clinical research and industry collaboration, successful commercialization could establish a groundbreaking treatment solution across multiple medical fields.

 

What kind of new future did this article inspire you to imagine? Feel free to share your ideas and insights in the comments! I’ll be back next time with another exciting topic. Thank you! 😊

 

Reference

1. Chen, Z. et al. (2021). "Bioorthogonal catalytic patch." Nature Nanotechnology, 16, 933–941.
2. Gao, X., Li, J., Li, J., Zhang, M., & Xu, J. (2024). "Pain-free oral delivery of biologic drugs using intestinal peristalsis–actuated microneedle robots." Science Advances, 10, eadj7067.
3. Tran, K. T. M. et al. (2021). "Transdermal microneedles for the programmable burst release of multiple vaccine payloads." Nature Biomedical Engineering, 5, 998–1007.
4. Yang, B., Kong, J., & Fang, X. (2022). "Programmable CRISPR-Cas9 microneedle patch for long-term capture and real-time monitoring of universal cell-free DNA." Nature Communications, 13, 3999.
5. Zhang, Y. et al. (2023). "Scarless wound healing programmed by core-shell microneedles." Nature Communications, 14, 3431.
6. Sang, M. et al. (2023). "Fluorescent-based biodegradable microneedle sensor array for tether-free continuous glucose monitoring with smartphone application." Science Advances, 9, eadh1765.
7. Kusama, S. et al. (2021). "Transdermal electroosmotic flow generated by a porous microneedle array patch." Nature Communications, 12, 658.
8. Chen, W. et al. (2017). "Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy." Nature Communications, 8, 1777.
9. He, G. et al. (2022). "Synthetic biology-instructed transdermal microneedle patch for traceable photodynamic therapy." Nature Communications, 13, 6238.
10. Kim, H. et al. (2024). "Skin preparation–free, stretchable microneedle adhesive patches for reliable electrophysiological sensing and exoskeleton robot control." Science Advances, 10, eadk5260.
11. Lin, K. et al. (2022). "Mechanism-based design of agents that selectively target drug-resistant glioma." Science, 377, 502–511.
12. Meng, J. et al. (2020). "A multistage assembly/disassembly strategy for tumor-targeted CO delivery." Science Advances, 6, eaba1362.
13. Yu, L., Hu, P., & Chen, Y. (2018). "Gas-generating nanoplatforms: Material chemistry, multifunctionality, and gas therapy." Advanced Materials, 30, 1801964.
14. Liu, P. et al. (2022). "Microneedle patches with O2 propellant for deeply and fast delivering photosensitizers: Towards improved photodynamic therapy." Advanced Science, 9, 2202591.
15. Zhao, P. et al. (2018). "Local generation of hydrogen for enhanced photothermal therapy." Nature Communications, 9, 4241.
16. Wang, D. et al. (2019). "A mesoporous nanoenzyme derived from metal–organic frameworks with endogenous oxygen generation to alleviate tumor hypoxia for significantly enhanced photodynamic therapy." Advanced Materials, 31, 1901893.
17. Chen, S. et al. (2023). "Local H2 release remodels senescence micro-environment for improved repair of injured bone." Nature Communications, 14, 7783.
18. Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. W. N. (2021). "Psoriasis." The Lancet, 397, 1301–1315.
19. Greb, J. E. et al. (2016). "Psoriasis." Nature Reviews Disease Primers, 2, 16082.
20. Shaw, L. P. et al. (2021). "Niche and local geography shape the pangenome of wastewater- and livestock-associated Enterobacteriaceae." Science Advances, 7, eabe3868.
21. Gao, Z. et al. (2023). "Microneedle-mediated cell therapy." Advanced Science, 11, 2304124.
22. Chen, H. et al. (2021). "Deep penetration of nanolevel drugs and micrometer-level T cells promoted by nanomotors for cancer immunochemotherapy." Journal of the American Chemical Society, 143, 12025–12037.
23. Lu, X. et al. (2023). "Single-atom catalysts-based catalytic ROS clearance for efficient psoriasis treatment and relapse prevention via restoring ESR1." Nature Communications, 14, 6767.
24. Wu, Y., Yuan, M., Song, J., Chen, X., & Yang, H. (2019). "Hydrogen gas from inflammation treatment to cancer therapy." ACS Nano, 13, 8505–8511.